Chardan Capital maintains Buy on Palvella Therapeutics; $240 target
Benzinga reports Chardan Capital maintained a Buy rating on Palvella Therapeutics and kept its $240.00/share price target.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Chardan Capital maintains Buy rating and $240 target on Palvella Therapeutics
Chardan Capital maintained a Buy rating on Palvella Therapeutics and reiterated a $240.00 price target, implying 59.4% upside versus the Sep 18 close of $150.56.